triiodothyronine has been researched along with Adverse Drug Event in 10 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These findings uncover WAT as a viable target mediating the therapeutic benefits of TH and provide a safe and efficient therapeutic strategy for obesity and its complications by delivering TH to adipose tissue." | 5.72 | Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects. ( Chen, K; Cheong, LY; Feng, T; Gao, Y; Honoré, E; Hui, X; Jin, L; Lam, KSL; Wang, Q; Wang, W; Xu, A; Zhang, Y, 2022) |
| " These findings uncover WAT as a viable target mediating the therapeutic benefits of TH and provide a safe and efficient therapeutic strategy for obesity and its complications by delivering TH to adipose tissue." | 1.72 | Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects. ( Chen, K; Cheong, LY; Feng, T; Gao, Y; Honoré, E; Hui, X; Jin, L; Lam, KSL; Wang, Q; Wang, W; Xu, A; Zhang, Y, 2022) |
| "Thyroid hormone extract is used for the treatment of thyroid disorders, but limited data exist on adverse events commonly noted by the physicians associated with this use." | 1.46 | ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT. ( Haugen, BR; Hennessey, JV; Levy, EG; Malabanan, A; Shrestha, RT, 2017) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Chen, K | 1 |
| Cheong, LY | 1 |
| Gao, Y | 1 |
| Zhang, Y | 1 |
| Feng, T | 1 |
| Wang, Q | 1 |
| Jin, L | 1 |
| Honoré, E | 1 |
| Lam, KSL | 1 |
| Wang, W | 1 |
| Hui, X | 1 |
| Xu, A | 1 |
| Shrestha, RT | 1 |
| Malabanan, A | 1 |
| Haugen, BR | 1 |
| Levy, EG | 1 |
| Hennessey, JV | 1 |
| Rosenthal, LJ | 1 |
| Goldner, WS | 1 |
| O'Reardon, JP | 1 |
| Wenzel, KW | 1 |
| Ghayad, E | 1 |
| Choueiri Medlej, R | 1 |
| Sapin, R | 1 |
| Schlienger, JL | 1 |
| Hall, NA | 1 |
3 reviews available for triiodothyronine and Adverse Drug Event
| Article | Year |
|---|---|
Disturbances of thyroid function tests by drugs.
Topics: Amiodarone; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Humans; Predic | 1996 |
[Changes in thyroid tests in non-thyroid diseases].
Topics: Disease; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperthyroxinemia; Thyroid Hormone | 1996 |
[A functional biologic study of the thyroid: pitfalls to avoid].
Topics: Age Factors; Aged; Child; Drug-Related Side Effects and Adverse Reactions; Humans; Thyroid Diseases; | 1999 |
7 other studies available for triiodothyronine and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Atherosclerosis; Drug-Related Side Effects an | 2022 |
ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Hor | 2017 |
T3 augmentation in major depressive disorder: safety considerations.
Topics: Adult; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Tr | 2011 |
The other edge.
Topics: Aged; Aspirin; Atropine; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imipramine | 1970 |